List of Imbruvica drug patents
Imbruvica is owned by Pharmacyclics Inc.
Imbruvica contains Ibrutinib.
Imbruvica has a total of 80 drug patents out of which 0 drug patents have expired.
Imbruvica was authorised for market use on 16 February, 2018.
Imbruvica is available in tablet;oral dosage forms.
Imbruvica can be used as treatment of chronic lymphocytic leukemia; treatment of small lymphocytic leukemia; treatment of chronic lymphocytic leukemia; treatment for chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma, treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia, treatment of relapsed or refractory small lymphocytic lymphoma; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of relapsed or refractory chronic lymphocytic leukemia, treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion; treatment of mantle cell lymphoma; treatment of marginal zone lymphoma; treatment of chronic lymphocytic leukemia; treatment of waldenstrom's macroglobulinemia, treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma, treatment of chronic lymphocytic leukemia; treatment of mantle cell lymphoma; treatment of small lymphocytic lymphoma; treatment of marginal zone lymphoma; treatment of chronic graft versus host disease after failure of one or more lines of systemic therapy; treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma with 17p deletion; treatment of chronic lymphocytic leukemia with 17p deletion, treatment of mantle cell lymphoma, treatment of refractory chronic graft-versus-host disease, for the treatment of patients with waldenstrom's macroglobulinemia; treatment of waldenstrom's macroglobulinemia, treatment of marginal zone lymphoma; treatment of mantle cell lymphoma; treatment of chronic lymphocytic leukemia; treatment of small lymphocytic lymphoma; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia, treatment of chronic graft versus host disease refractory to systemic therapy, treatment of small lymphocytic lymphoma; treatment of chronic small lymphocytic leukemia; treatment of waldenstrom's macroglobulinemia; treatment of chronic lymphocytic leukemia, treatment of waldenstrom's macroglobulinemia, treatment of chronic graft-versus-host disease; treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy, treatment of chronic lymphocytic leukemia, treatment of marginal zone lymphoma, treatment of marginal zone lymphoma; treatment of small lymphocytic lymphoma; treatment of small lymphocytic lymphoma with 17p deletion; treatment of waldenstrom's macroglobulinemia; treatment of mantle cell lymphoma, treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.
The generics of Imbruvica are possible to be released after 03 September, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8735403 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US7514444 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8957079 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US9181257 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8697711 | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8008309 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Nov, 2027
(4 years from now) | |
| US9725455 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10125140 | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10106548 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9296753 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Oct, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8476284 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8497277 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8952015 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8703780 | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8754091 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Dec, 2026
(3 years from now) | |
| US8563563 | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Apr, 2027
(3 years from now) | |
|
US9181257 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8497277 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8957079 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US7514444 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8735403 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8697711 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton'S tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8476284 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8952015 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8754091 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8703780 (Pediatric) | PHARMACYCLICS INC | Inhibitors of Bruton's tyrosine kinase |
Jun, 2027
(4 years from now) | |
|
US8563563 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
Oct, 2027
(4 years from now) | |
|
US8008309 (Pediatric) | PHARMACYCLICS INC | Inhibitors of bruton's tyrosine kinase |
May, 2028
(4 years from now) | |
| US10016435 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9814721 | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US10478439 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801881 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
| US8754090 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9125889 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US8999999 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US9801883 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10004746 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10751342 | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Jun, 2031
(8 years from now) | |
| US10653696 | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Jun, 2031
(8 years from now) | |
|
US10478439 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10004746 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US8754090 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US8999999 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9125889 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US9801881 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US9814721 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
|
US9801883 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10016435 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10751342 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
Dec, 2031
(8 years from now) | |
|
US10653696 (Pediatric) | PHARMACYCLICS INC | Use of inhibitors of bruton's tyrosine kinase (BTK) |
Dec, 2031
(8 years from now) | |
| US10752634 | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10961251 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9713617 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294231 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US10294232 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Jun, 2033
(10 years from now) | |
| US9540382 | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Aug, 2033
(10 years from now) | |
|
US10961251 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10106548 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9725455 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10125140 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10752634 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a brutons tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294231 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US10294232 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9713617 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Dec, 2033
(10 years from now) | |
|
US9540382 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(10 years from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS INC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(10 years from now) | |
| US9795604 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10695350 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
| US10463668 | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(11 years from now) | |
|
US10695350 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US10463668 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
|
US9795604 (Pediatric) | PHARMACYCLICS INC | Methods of treating and preventing graft versus host disease |
Apr, 2035
(11 years from now) | |
| US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
| US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(12 years from now) | |
|
US10828259 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US9655857 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10010507 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
|
US10213386 (Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 24, 2029 |
| ODE* (ODE*) | Aug 2, 2024 |
| New Patient Population (NPP) | Aug 24, 2025 |
| Pediatric Exclusivity (PED) | Feb 24, 2030 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of marginal zone lymphoma; Treatment of small lymphocytic lymphoma; Treatment of small lymphocytic lymphoma with 17p deletion; Treatment of waldenstrom's macroglobulinemia; Treatment of mant...
Dosage: TABLET;ORAL
IMBRUVICA family patents
167
United States
27
Japan
22
European Union
21
Canada
21
Australia
16
New Zealand
16
Korea, Republic of
13
China
12
Israel
10
Singapore
10
Hungary
9
Spain
9
Mexico
8
Poland
8
EA
8
South Africa
8
Slovenia
7
Denmark
7
Cyprus
7
Portugal
7
Taiwan
7
Lithuania
6
Philippines
6
Brazil
5
Hong Kong
4
Argentina
4
Chile
3
Dominican Republic
3
Morocco
3
Luxembourg
2
Uruguay
2
Ukraine
2
Peru
2
Jordan
2
Ecuador
1
Austria
1
Malaysia
1
Russia
1
Guatemala
1
Costa Rica
1
Netherlands
1
Colombia
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic